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A B S T R A C T   
Platelets are small enucleated cell fragments specialized in the control of hemostasis, but also playing a role in 
angiogenesis, inflammation and immunity. This plasticity demands a broad range of physiological processes. 
Platelet functions are mediated through a variety of receptors, the concerted action of which must be tightly 
regulated, in order to allow specific and timely responses to different stimuli. Protein phosphorylation is one of 
the main key regulatory mechanisms by which extracellular signals are conveyed. Despite the importance of 
platelets in health and disease, the molecular pathways underlying the activation of these cells are still under 
investigation. Here, we review current literature on signaling platelet biology and in particular emphasize the 
newly emerging role of phosphatases in these processes.   
1. Introduction 
The human body has in the order of 1012 circulating platelets. Their 
average life span is 7–10 days, after which they are removed from the 
circulation and cleared by splenic or hepatic macrophages and hepato-
cytes. With a size of around 2–3 μm diameter, a discoid shape, and a 
minimal displacement volume coupled with a highly active cytoskel-
eton, platelets are well suited to vascular circulation. As the first re-
sponders to tissue damage, platelets are principle regulators of 
hemostasis. However, as suppliers of growth factors they also induce 
blood vessel formation and play a pivotal role in the wound healing and 
regenerative processes contributing to tissue repair. Additionally, a role 
for platelets in immunity is now emerging - having retained several of 
the functions associated with their myeloid origin, platelets have the 
ability to internalize environmental factors such pathogens through 
phagocytosis [1]. Binding of bacteria via toll like receptors may facili-
tate the recruitment and subsequent uptake of bacteria by granulocytes 
[2]. Platelets also contribute to adaptive immunity, by activating den-
dritic cells and enhancing their antigen presentation in the context of 
major histocompatibility complex (MHC)II molecules to T or B cells [3], 
while MHCI molecules taken up from serum can be used to present 
antigens to T-cells [4]. Thus, platelets are versatile cells which play an 
important role in human physiology. While a protagonist in hemostasis, 
excessive platelet activation is also a major cause of morbidity and 
mortality in western societies. It is therefore not surprising that platelets 
have become extensively investigated. Nevertheless, precisely how 
platelets become activated under physiological and pathophysiological 
conditions is still under investigation. 
Despite the fact that platelets do not contain a nucleus and are hence 
incapable of transcribing new mRNA molecules, they do retain the ca-
pacity to synthesize their own functional proteins from mRNAs inherited 
from the megakaryocytes from which they derive. Alternative splicing 
and signal-dependent translation of the 3000–6000 platelet mRNA 
transcripts thus far identified may give rise to new proteins [5]. 
Furthermore, protein modification through functional proteasomes and 
ubiquitin complexes can take place. However, one of the most important 
post-translational protein modifications, allowing platelets to fulfil their 
highly dynamic and diverse functions [6,7], comes from protein phos-
phorylation. Reversible phosphorylation of proteins, catalyzed by 
phosphorylating kinases and dephosphorylating phosphatases, plays a 
role in almost every cellular aspect. Contact of platelets with extracel-
lular ligands causes a fast and transient burst in kinase activity and a 
substantial augmentation of intracellular phosphorylation. However, 
although much is known regarding the kinases governing platelet 
functionality, comparatively little is known with regards to phospha-
tases in this context. In the early 90’s, platelets were recognized to 
contain at least 6 independent phosphatases with activity towards actin- 
related proteins including myosin light chain (MLC), however these 
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remained unnamed and were speculated to merely reduce platelet 
activation [8]. Subsequent studies have shown that platelets contain 
many more phosphatases, and that their role is not always so straight-
forward. Therefore, in this review, we will discuss the recent advance-
ments in our knowledge regarding the phosphatases governing platelet 
plasticity in response to different stimuli. 
2. Phosphorylation in platelets 
Cellular communication depends on the binding of adhesion mole-
cules, cytokines, chemokines or growth factors to ligand-specific re-
ceptors at the cellular membrane, ensuring amplification of the received 
information and execution of a specific cellular response. In this 
signaling cascade, activation or inhibition of enzymes is often deter-
mined by their phosphorylation status. Zahedi and colleagues investi-
gated the phosphoproteome from healthy human platelets, and 
demonstrated that almost 280 proteins were phosphorylated on 
different sites, with 55% of these proteins related to signaling pathways 
and cytoskeletal dynamics [8]. Thus, phospho-signaling in platelets is 
evidently important, and a better understanding of these signaling 
events may provide insight into platelet biology in health as well as 
pathological conditions (Fig. 1). Protein phosphorylation is restricted to 
only a few amino acid residues, and according to their specificity, ki-
nases and phosphatases are thus classified as being tyrosine, serine/ 
threonine or dual specificity enzymes. Over 500 protein kinases are 
encoded by the human kinome, many of which are expressed in plate-
lets. Although full functional characterization is mainly limited to a few 
main signaling pathways, our knowledge of these pathways is relatively 
well advanced [9–12]. In contrast, the human genome contains far fewer 
phosphatase genes, with a total of 107 protein tyrosine phosphatase 
(PTP) and ~ 30 serine/threonine phosphatases thus far identified [13]. 
PTPs can be further subdivided into four classes (I-IV), depending on 
their structural features and specificity. Class I consists of the classical 
PTPs (further subdivided into receptor PTPs and non-receptor type 
PTPs) and dual specificity phosphatases. Class II only contains the low 
molecular weight PTP (LMWPTP), while class III contains three CD25- 
like PTPs. In contrast to the cysteine-based PTPs in class I to III PTPs, 
Class IV contains aspartate-based PTPs. 
Of the classical PTPs, sixteen were identified in platelets using a 
specialized PTP-proteomics approach [14], with several others identi-
fied by conventional proteomics, making a total tally of 10 receptor-like 
and 10 non-receptor PTPs present in platelets [15,16]. Serine/threonine 
phosphatases, including PP1, PP2, PP3, PP6 have also been identified in 
platelets [17–20], as well as the dual specificity phosphatases DUSP3 
and MTM1 [18]. In addition, the novel histidine phosphatase TULA-2 
has been shown to be present in platelets [21], as is LMWPTP [22]. 
We summarized the expressed phosphatases reported in platelets of the 
tyrosine, serine-threonine and dual-specificity phosphatases in Fig. 2. 
Lipid phosphatases, while not the main topic of this review, have also 
been shown in platelets [23]. Over the past few years, more and more 
studies have revealed that phosphatases are relevant modulators of 
platelet function, although the underlying mechanisms are still poorly 
understood. It is of interest to note that pan protein tyrosine phosphatase 
activity is increased in platelets in response to collagen stimulation, 
Fig. 1. Platelet function. Platelet activation is modulated by the interaction of several agonists with specific receptors. After the activation through diverse stimuli, 
platelets change their shape to spread and expose adhesion molecules, which supports adherence and triggers granule release, further amplifying the aggregation 
process. Following the platelet activation, platelets releases pro-inflammatory factors for wound healing, tissue regenerations and angiogenesis by transporting and 
delivering factors. 
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suggesting their role in adhesive processes (Fig. 3). However, in contrast 
to collagen, thrombin stimulation reduces total PTP activity (Fig. 3), 
demonstrating ligand-specific regulation of phosphatase activity in 
platelets. Below, we summarize the ligand-receptor-signaling events 
involved in hemostasis and review what is currently known regarding 
the best described of these phosphatases in platelet activity. 
3. Platelet receptors, their ligands and hemostasis 
In order to perform their functions, platelets carry an array of 
membrane receptors allowing them to respond to various extracellular 
ligands. Of the extended family of integrins, platelets carry six: α2β1 
(CD49b/CD29), ανβ1 (CD49e/CD29), α6β1 (CD49f/CD29), αLβ2 
(CD11a/CD18), αІIbβ3 (CD41/CD61), and ανβ3 (CD51/CD41) [20,24]. 
Of these, arguable the best studied are the highly expressed αIIbβ3 [20], 
which is recognized by fibrinogen, von Willebrand factor (vWF) and the 
extracellular matrix components fibronectin and vitronectin, and the 
collagen receptor α2β1 (otherwise known as glycoprotein GPIa/IIa). 
Collagen is additionally recognized by GPVI. The second most abundant 
platelet receptor is the glycoprotein receptor complex GP1b-IX-V, which 
primarily binds to vWF, but also recognizes thrombin, P-selectin, and 
clotting factors XI and XII [25]. Thrombin is also able to stimulate 
platelets via the protease activated receptor (PAR)1 and PAR4 (see 
Fig. 1). 
The first step towards thrombus formation is the deceleration of 
platelets through binding of their GPIb-V-IX receptor complex to vWF 
captured onto collagen fibrils exposed at the sub-endothelial matrix 
lining of the vessel upon injury [26,27]. This interaction is stabilized by 
subsequent binding of α2β1 to collagen and αIIbβ3 binding to vWF/ 
fibrinogen [20,27,28]. After formation of a monolayer of platelets 
attached to the vessel wall, homotypic platelet interactions mediated by 
GPIb-V-IX and αIIbβ3 binding to their ligands causes platelet aggrega-
tion. Subsequent adhesion-dependent signals, including GPVI binding to 
collagen, triggers activation of the platelets [29], which is further 
extended by locally generated or secreted factors like thrombin, ADP, 
epinephrine and thromboxane A2 (TxA2). At this stage, the activated 
platelet changes its morphology from a discoid shape to a flattened 
shape with lamellipodia, thus increasing their surface area and 
providing a scaffold for other aggregating platelets (Fig. 1A) [30–32]. In 
the last steps of platelet activation, conformational changes in integrin 
αIIbβ3 resulting in enhanced affinity for its ligands, allows fibrinogen to 
act as a bridging molecule, tethering platelets together [33,34]. The 
inside-out signaling required to initiate these conformational changes 
appears to be mediated largely through thrombin-mediated signaling via 
PAR1, and depends on actin-binding intermediator proteins such as 
talin, kindlins and the ezrin-radixin-moesin (ERM) family of proteins 
[35,36]. In addition to forming a platelet plug during primary hemo-
stasis, platelets contribute to secondary hemostasis (the coagulation 
cascade) through their release of coagulation Factors V, XI, and XIII, pro- 
thrombin and fibrinogen, all of which feed into the coagulation cascade. 
This series of catalytic steps culminates in the cleaving of fibrinogen by 
thrombin to form adhesive monomeric fibrin fibrils, which further 
Fig. 2. Protein phosphatases described in platelets. Summary of protein 
phosphatases described in platelets on expression level, and functional analysis 
described [92,135–144]. 
Fig. 3. Total tyrosine phosphatase activity assay in 
stimulated platelets. After signed informed consent was 
obtained (Ethical committee Project NL66029.078.18 
approved by Erasmus MC medical and ethical commit-
tee), venous blood from healthy donors (n = 3) (all of 
them drug-free) was collected into conical plastic tubes 
containing 3.8% trisodium citrate 1:10 (v/v). Whole 
blood was centrifuged at 1500 rpm, 10 min, 22 ◦C, and 
Platelet-Rich Plasma (PRP) was collected. NaCl (0.9%) 
was used to wash the platelets. Washed platelets were 
incubated with a final concentration of 2 μg/mL 
Collagen or 1 U/mL Thrombin for 10 min. All experi-
ments were performed using 200–300 x 103platelets/μL. 
Platelets were lysed with 100 μL of lysis buffer (20 mM 
HEPES, pH 7.4 with 2.5 mM MgCl2, 0.1 mM EDTA) on 
ice for 2 h. After clarifying by centrifugation, protein- 
normalized platelets extracts were incubated in acetate 
buffer and the enzyme activity was assessed as followed: 
reaction medium (100 μL) contained 100 mM acetate 
buffer, 5 mM p-nitrophenyl phosphate (pNPP). After 60 
min, at 37 ◦C and under agitation (600 rpm) the reaction 
was stopped by adding 100 μL 1 M NaOH. The absor-
bance was measured at 405 nm (spectrophotometer - 
BioRad, California, USA). Statistical analysis was per-
formed using t-student (paired, 95% confidence in-
tervals, one-tailed) using GraphPad (GraphPad Inc., 
version 5.0, California, USA) - (A.V.S. Faria, unpub-
lished data).   
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constructs stable bridges between platelets [37]. 
It is of interest to note that platelets carry many components capable 
of enhancing their own activation. Among others, the fibrin precursor 
fibrinogen, GPVI, αIIbβ3, P-selectin, and bioactive molecules such vWF, 
are contained within α-granules [38,39]. Furthermore, dense-granules, 
lysosome-related organelles with a cargo profile that is dominated by 
smaller molecules, contain serotonin, ADP/ATP and Ca2+ [40]. Exocy-
tosis of these granules can be triggered by specific platelet agonists and 
enhances expression of granule-specific membrane phospholipids, gly-
coproteins and integrins. Many of these membrane components play an 
essential role in platelet adhesion and aggregation, and their release can 
therefore enhance platelet activation cascades. Furthermore, as platelets 
themselves carry receptors for many of the vesicle components, 
including ADP receptors P2Y1, P2Y12 and the ATP receptor P2X1, release 
of these factors allows autocrine activation [41]. 
4. Signaling via platelet receptors during hemostasis and 
thrombus formation 
4.1. G-protein coupled receptor signaling 
GPCRs receptors are coupled to heterotrimeric G-proteins, Gα, Gβ 
and Gγ, of which in particular the type of Gα subunit determines the 
signaling outcome. Four main Gα proteins can be distinguished: Gαq, 
Gαs, Gαi and Gα12/13. Platelet Gαq receptors include the receptors for 
thrombin [42], TxA2 and the P2Y1 ADP receptor. Binding of a Gαq- 
coupled receptor leads to activation of phospholipase C, which in turn 
cleaves the membrane-bound inositol lipid phosphatidylinositol 
biphosphate (PIP2) to diacylglycerol (DAG) and inositol 3-phosphate 
(IP3) [43]. Subsequent binding of IP3 receptors at the endoplasmic re-
ticulum leads to release of intracellular Ca2+ stores, while DAG binds 
and activates the serine/threonine Protein Kinase C (PKC), together 
leading to further intracellular signal transduction and cellular re-
sponses. Gαs and Gαi proteins act by stimulating or inhibiting the 
enzyme adenylate cyclase (AC), respectively. AC activity triggers the 
formation of the second messenger cyclic-AMP (cAMP) resulting in 
activation of cAMP-dependent Protein Kinase A (PKA), a potent inhib-
itor of platelet function [44]. While prostaglandins and adenosines in-
crease cAMP levels via Gαs, the thrombin receptor PAR1, as well as the 
ADP receptor P2Y12, signal through Gαi (as well as Gq), thereby 
reducing activation of the serine/threonine PKA kinase [45]. Different 
isoforms of PKA exist, which may localize to different cellular com-
partments and play different roles in platelet activation [46] suggesting 
that PKA signaling in platelets is complex and multifunctional [45]. 
Lastly, signaling via Gα12/13 occurs via PAR4 and the TxA2 receptors, 
and activates cytoskeletal rearrangement and platelet shape changes 
[47]. 
Phosphotyrosine profiling shows that total cellular tyrosine phos-
phorylation increases upon stimulation with ATP, and is near 
completely abolished by concurrent treatment of cells with PKA- 
activating prostacyclin analogue iloprost [48]. This suggests that ki-
nase activity does not indiscriminately result in enhancement of platelet 
functions, as is often thought. Indeed phosphorylation of GP1bβSer166 by 
PKA can reduce its binding to vWF under flow conditions [49]. Large 
scale phosphoproteomics confirmed that inhibition of platelet functions 
through stimulation with prostacyclin (activating cAMP/PKA signaling) 
is indeed accompanied by upregulation of phosphorylation of several 
kinases, including GRP2Ser587, SrcTyr530, VASPSer157, VASPSer239, 
GSK3αSer21, GSK3βSer9, ZyxinSer142/143, Filamin-ASer2152, LASPSer14. 
However, many of these phosphorylation reactions reduce activity of the 
associated protein, which may in part account for the inhibition of 
platelet functioning [50–52]. In addition, phosphorylation of 3 phos-
phatases, namely PTPRJSer1311 (increased), CTDSPLSer32 (decreased), 
and PTPN12Ser332 (decreased) were affected by prostacyclin stimula-
tion. To what extent these contribute to inhibition of platelet signaling in 
response to Gαs signaling remains to be established (for more details on 
PTPRJ, see below) [44]. 
4.2. Tyrosine kinase (associated) receptor signaling 
The main tyrosine kinase-associated receptors involved in platelet 
activation are GPIb-IX-V and GPVI. Neither of these contain intrinsic 
kinase activity; instead, they rely on a family of protein-tyrosine kinases 
(PTKs) that are either associated with or in close proximity to their 
cytoplasmic tails, to transmit signals. For GPVI, this is provided by 
coupling with Fcγ-receptors, which have an intracellular domain con-
taining an immunoreceptor tyrosine activation motif (ITAM). Upon 
ligand binding, ITAM motifs become phosphorylated by the Src family 
kinases (SFK, including Src, Syk, Fyn, Lck, Btk, Fgr, Lyn, Yes), which 
results in tyrosine phosphorylation of the membrane adaptor protein 
LAT (linker of activation of T-cells), in turn activating multiple signal 
transduction pathways including PLCγ and the lipid kinase 
phosphatidyl-inositol 3-OH kinase (PI3K) [53,54]. For GPIb/IX/V, the 
associated tyrosine kinase appear to be less well known, and signaling 
could be either via FcγRII, directly through Src, or via PI3K [54]. It has 
also been suggested that FcγRII-ITAM signaling contributes to outside-in 
signaling of integrins, with in particular Fyn and Syk contributing to 
phosphorylation of αІIbβ3 integrin, leading to PLCγ activity [47,55]. 
Other tyrosine kinase receptors present on the surface of human plate-
lets include the thrombopoietin receptor (or c-MPL), the TAM family 
(Tyro3, Axl, and Mer), ephrins and the IGF-1 receptor [54]. 
Downstream signaling of tyrosine kinase (associated) receptors is 
complex, and in platelets appears to depend to a large extent on SFK 
activity (for review see [10]). vWF interaction with GPIb-V-IX leads to 
activation of SFK as well as Phospholipase A2, initiating platelet acti-
vation by changing its cytoskeletal arrangement [10,53]. Collagen 
stimulation of the receptors αIIbβ3, GPIb, GPVI and FcγR also results in 
SFK activation [53]. Furthermore, in platelets activated by thrombin, 
Ca2+-mediated activation of SFK results in activation of Pyk (a member 
of the focal adhesion kinase [FAK] family) [56], both described as 
master regulators of cytoskeletal remodeling in response to thrombin, 
showing that GPCR signaling also converges on tyrosine phosphoryla-
tion signaling [57,58]. This is further demonstrated by the converse fact 
that collagen stimulation results in Ca2+-dependent activation of PKC- 
α/β which promotes α-granule release [59]. Activation of SFK in plate-
lets leads to activation of other intracellular kinases, including PI3K/ 
protein kinase B (otherwise known as Akt). For instance, α2β1 and 
αIIbβ3 activate SFK and PLC signaling, which coordinates PI3K/Akt 
activation [9,60]. PI3K was also associated with platelet aggregation in 
response to ADP stimulation [61,62], as well as thrombin [58]. Down-
stream of Src-PI3K signaling, Akt phosphorylation was confirmed to play 
an important role in collagen- and ADP-induced platelet aggregation 
[61]. In addition to Src and PI3K signaling, members of mitogen acti-
vated protein kinase (MAPK) family (e.g. ERK and p38) have generally 
been considered positive modulators of platelet function. Binding of 
vWF or thrombin to GPIb-IX-V results in activation of integrin αIIbβ3, an 
example of inside-out-signaling, and this process depends on both PKC 
and ERK activities [63]. Activated ERK is described to play an important 
role in platelet aggregation, morphological changes and clot retraction 
[64]. p38 is also known to be activated by Src phosphorylation in 
response to collagen or thrombin. However, the role of ERK and p38 are 
dissimilar, with p38, but not ERK, mediating collagen-induced adhesion 
under static conditions and ERK regulating collagen/GP1b-vWF in-
teractions and p38 mediating collagen-αІIβ1 interactions under shear 
conditions [65,66]. The principal functions coordinated by p38 are 
cytoskeleton remodeling and Ca2+ release, and consequently, amplifi-
cation of platelet aggregation [67]. 
The general kinase receptor-induced pathways described here are 
common among many different cell types, and phosphatases modulating 
these pathways have been identified in several cellular settings. Below, 
we describe in more detail what is known about these phosphatases 
signaling in the dynamic modulation of phosphoprotein content in 
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platelets. 
5. Phosphorylation and dephosphorylation in platelet shape 
change and degranulation 
Actin cytoskeletal rearrangement is required for platelet shape 
change, contraction, degranulation and aggregation. Serine phosphor-
ylation of MLC, causing the formation of cross-bridges between myosin 
and actin, plays an important role in these processes [68]. Activation of 
MLC can be achieved through both Gαq and Gα12/13 pathways. For 
instance, Gαq/PLCβ activation through thrombin modulates platelet 
shape changes via IP3-Ca2+ signaling [69] Early studies already indi-
cated that in addition to PLC/PKC signaling, thrombin-mediated platelet 
aggregation relies on activation of tyrosine- and serine/threonine 
phosphatases [70]. While the exact phosphatases remained to be 
elucidated at that time, later studies demonstrated that activation of 
diverse PKC isoforms inhibits the MLC phosphatase (MLCP), thereby 
allowing MLC phosphorylation and stimulation of platelet granule 
secretion [71,72]. Activation of Gα12/13 by for instance TxA2 also results 
in phosphorylation of MLC and shape changes, but in this case depends 
on Ca2+-independent signaling, including Src and Rho-kinase activation 
[70,71], which in turn phosphorylate and inactivate MLCP. Similarly, 
PAR4-mediated Gα12/13 activity activates Pyk2, regulating platelet ag-
gregation and dense granule release [72], and MLCP appears to be the 
target of Pyk2 signaling through this G-protein [72]. In contrast, pros-
taglandin-Gαs-activated PKA activity inhibits the Rho kinase and en-
hances MLCP activity, thereby attenuating the actin cytoskeleton 
rearrangements required for platelet shape changes [73]. In addition to 
GPCR signaling, collagen/αIIb mediated degranulation has also been 
linked to MLC phosphorylation [68], although in this case via ERK- 
mediated activation of the MLC kinase. Thus, a complex series of acti-
vating and inactivating phosphorylations of both kinases and phospha-
tases converge on MLC-mediated modulation of the platelet 
cytoskeleton. 
MLC-independent pathways of platelet shape change/degranulation 
have also been described to rely on phosphatase activity. Ca2+-depen-
dent but PKC-independent platelet dense granule release induced by 
thrombin was shown to be mediated via the Ca2+/calmodulin-depen-
dent phosphatase calcineurin, through activation of the Rho GTPase Rac 
and dephosphorylation of the actin modulator cofilin [74,75]. The lipid 
phosphatase SHIP1 also modulates dense granule release. Collagen- 
GPVI stimulation of platelets results in SFK-mediated activation of 
SHIP1, which associates with PKC-δ and inhibits granule release. In 
contrast, thrombin-stimulated PKC-δ activity does not coincide with 
SHIP1 association and stimulates dense granule secretion [76]. The 
complexity of PKC signaling is further demonstrated by the fact that (as 
mentioned above) α-granule release in response to collagen is stimulated 
by PKC-α/β, while collagen-induced PKC-θ negatively modulates 
α-granule degranulation, and PKC-δ has no effect [59]. In addition, 
tyrosine kinase receptors, including Axl and Tyro3 mediated Syk/PLCγ 
signaling also play important role in platelet activation, especially in 
α-granule release and spreading, although the role of phosphatases in 
these signaling cascades remains unstudied [54]. 
In addition to the actin cytoskeleton (the microfilaments), microtu-
bules play an important role in platelet physiology, in particularly in 
maintaining platelet discoid shape, regulating intracellular transport of 
vesicles and their degranulation [77]. α-Tubulin, the building blocks of 
microtubules, undergo many post-translational modifications in acti-
vated platelets, resulting in reorganization of the microtubule cyto-
skeleton and contributing to platelet aggregation [78,79]. Tubulin is 
phosphorylated in unstimulated platelets and loses phosphorylation 
levels upon stimulation with agonists [80,81] such as thrombin or 
collagen (although this was disputed by others) [82], however it is un-
clear to what extent phosphatases contribute to this process. Neverthe-
less, MLC-independent PP1 and PP2-mediated dephosphorylation of a 
90 kDa target was shown to contribute to both actin and microtubule 
dynamics in platelets [83], although in this case the target was not 
identified. Taken together, both microfilament and microtubule dy-
namics in platelets are modulated by phosphatase activity although the 
direct extent to which phosphatases are involved requires further 
elucidation. 
6. The role of phosphatases in hemostasis and thrombus 
formation 
6.1. ITIMs, GPCRs and SHP 
Platelet activation via ITAM motif-coupled receptors is counteracted 
to large extent by immunoreceptor tyrosine-based inhibitory domain 
(ITIM)-containing receptors. The best described of these in platelets are 
PECAM-1, which mainly inhibits collagen-mediated activation of the 
GPVI-FcRγ-chain complex, and G6b-B, which reduces signaling from 
GPVI-FcRγ as well as the hemiITAM-containing receptor for podoplanin; 
CLEC2. In addition to an ITIM motif, PECAM-1 and G6b-B contain an 
immunoreceptor tyrosine-based switch motif (ITSM) [84]. Phosphory-
lation of both ITAM and ITIM/ITSM by SFKs creates docking sites for 
SH2-domain containing proteins. But while for ITAM this results in 
recruitment of protein-tyrosine kinase Syk and downstream activation of 
(tyrosine) kinase signaling and Ca2+ release, ITIM/ITSMs recruit the 
SH2-domain containing phosphatases SHP1 (i.e. PTP1C, PTPN6) and 
SHP2 (i.e. PTP1D, PTP2C, PTPN11), which is associated with inhibition 
of platelet function [85]. SHP2 may directly dephosphorylate the ITAM 
receptor itself (as was shown for CLEC-2 in the case of G6b-B), but also 
may target the kinase Syk [84–86]. Additionally, it has been suggested 
that PECAM-1 itself may be a target (although the role for this in 
platelets is unclear) and that recruitment of PI3K to SHP1 prevents its 
activation by molecules associated with LAT (although this appears to be 
independent of its phosphatase activity [87–89]. Under collagen stim-
ulation, the formation of reactive oxygen species causes transient 
oxidation of SHP2, which inactivates its phosphatase activity and allows 
activation of Syk, Vav and Btk in the LAT complex, resulting in platelet 
activation and degranulation [90]. It should be noted that association of 
SHP2 with the non-classical ITIM-bearing receptor TREM-like 1 (TL1), 
actually enhances α-granule release, adding a layer of complexity to SHP 
signaling [91]. 
The role of SHP1 and SHP2 has also been investigated in non-ITIM- 
mediated signaling in platelets. As already alluded to above, GPCR 
signaling activates kinase signaling and phosphorylation patterns which 
are also subject to phosphatase regulation. One study showed that PKC- 
mediated phosphorylation of SHP1Ser591 in response to thrombin-PAR1/ 
4 stimulation inhibits SHP1 activity, which subsequently increases 
phosphorylation of its substrate, the guanine-nucleotide exchange factor 
Vav, a regulator of cytoskeletal rearrangement [89]. Indeed, overall, the 
general consensus appears to favor a negative modulatory role for SHP 
phosphatase activity in platelet adhesion [90]. However, several studies 
indicate that the role of SHP phosphatases may be more complicated. 
SHP1Tyr536 and SHP1Tyr564 phosphorylation in response to thrombin 
were shown to activate SHP1 enzymatic activity [93], independently 
from integrin and PKC signaling [94]. As the Src kinase is a direct sub-
strate of SHP1, this would paradoxically dampen thrombin-mediated 
responses. However, some studies showed that this may be a late 
event during thrombin signaling (upon 45 min stimulation), and 
therefore present a means to prevent over-activation of thrombus for-
mation [95]. Furthermore, by targeting the negative tyrosine regulatory 
site of Src kinase, SHP1 activity may actually enhance Src activity and 
platelet function [96]. Additionally, it was demonstrated that Gαq- 
mediated signaling causes rapid (within seconds) degradation of a 
protein complex which keeps resting platelets inactivated, and this 
process is dependent on phosphorylation and activation of SHP1 [97]. 
Overall, both positive and negative roles for SHP1 have been described 
in platelets and the exact role for SHP1 in platelet function therefore 
remains elusive [97,98]. Experiments in knock-out mice have 
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demonstrated that megakaryocyte-specific Shp1 deficiency leads to 
reduced platelet spreading, while Shp2 deficiency increases platelet 
spreading on fibrinogen, demonstrating opposite effects of these phos-
phatases on at least some platelet functions [99]. Consistently, in vivo 
thrombosis was only reduced in Shp1 but not Shp2 knock-out mice [99]. 
Both gain-of-function and loss-of-function mutations of SHP2 are found 
in humans: gain-of function mutations as seen in patients with Noonan 
syndrome (often associated with bleeding) cause reduced collagen- 
induced (but not thrombin or ristocetin-induced) platelet aggregation, 
while loss-of-function of SHP2 in patients with Noonan syndrome with 
multiple lentigines show normal aggregation, but increased collagen- 
adherence under shear stress [100]. This would suggest that SHP2 
negatively modulates collagen-induced platelet reactions. Indeed, Shp2- 
deficient mouse platelets form more stable thrombi on collagen under 
shear stress as compared to wild type platelets [101]. However, while 
Shp2 downregulates αІIbβ3 outside-in signaling and reduces TxA2- 
mediated dense granule release, no effect of Shp2-deficiency was seen 
on collagen, thrombin, or ADP-mediated aggregation or dense granule 
release [101]. On the other hand, stimulation of platelets with thrombin 
(via PAR4) results in association of SHP2 with PI3K and Pyk in human 
platelets, which together seems to stimulate platelet aggregation, 
despite the presence of phosphatase activity in this complex. Thus, SHP2 
activity may either control the thrombin-induced signal or actually 
enhance it [102]. 
6.2. Positive modulation of SFK via CD148 and PTP1B 
One of the first transmembrane PTPs identified in platelets is the 
receptor-like protein-tyrosine phosphatase (PTP) CD148, also known as 
PTPRJ, which is expressed in all hematopoietic cells. It is known to 
dephosphorylate PLCγ1 and LAT, thereby inactivating signaling through 
the T-cell receptor CD3 in T-cells, while dephosphorylation of SFKs 
contributes to neutrophil migration [103,104]. It is tempting to specu-
late that CD148 may contribute to the immunological functions of 
platelets as well. While one of the main substrates of this phosphatase is 
the platelet derived growth factor receptors (PDGFR), in platelets this 
phosphatase is best known for its ability to modulate activity of the SFKs 
[105]. Knockdown of CD148 in mouse models was shown to increase 
Lyn and Src phosphorylation at their inhibitory sites, while reducing 
phosphorylation in their activation loops. In turn, this resulted in 
impaired platelet spreading on fibrinogen, suggesting a requirement of 
this phosphatase in integrin αIIbβ3 signaling. GPVI-dependent platelet 
aggregation and ATP secretion were also dependent on CD148 activity. 
Thrombin-induced aggregation and ATP secretion as well as CLEC-2- 
mediated platelet activation were only partly affected by CD148 
knock-down, while ADP-induced responses were not affected at all, 
showing selective requirement of this phosphatase by specific platelet 
agonists [106]. Knockdown of CD148 reduces thrombosis in mice, 
suggesting that CD148 inhibition may be beneficial for to limit or treat 
thrombotic events [107]. In humans, it has recently been shown that 
loss-of-function mutations in CD148 cause a form of hereditary throm-
bocytopenia, with patients showing reduced pro-platelet formation as 
well as reduced GPVI-mediated Src activation and platelet responses 
[106]. Thus, the general consensus is that CD148 contributes to platelet 
activation by releasing inhibitory phosphorylation on SFK. However, a 
recent study suggests that CD148 may also reduce phosphorylation of 
SFKs at their activation loop. However, this is likely required to limit 
platelet over-activation, and indeed over-activation of SFK signaling 
may provide a negative feedback loop [108]. 
While CD148 was shown to be essential for platelet activity, full 
aggregate formation also requires the phosphatase PTP1B, another 
positive modulator of SFK [109]. Platelet expression of the non- 
transmembrane PTP1B (also known as PTPN1) was already described 
decades ago. This phosphatase can become activated upon proteolytic 
cleavage by calpain in response to αIIbβ3 integrin stimulation [110]. 
This in turn reduces the FcyRIIa-mediated phosphorylation of LAT, 
resulting in cytoskeletal rearrangement and irreversible platelet aggre-
gation [111]. This suggests that PTP1B activity is required for full 
platelet responses, and indeed, PTP1B deficient platelets fail to form full 
aggregates on collagen [107]. Upon fibrinogen stimulation of platelets, 
PTP1B is recruited to interact with αIIbβ3 and promotes Src kinase 
activation by dephosphorylation of its inhibitory site [107,112]. This 
results in αIIbβ3 outside-in signaling and adhesion of platelets to 
fibrinogen. These functions are very similar as those reported for CD148, 
but while CD148 appears to regulate SFK more generally, PTP1B 
involvement is more specific to αIIbβ3 integrin signaling [105,113]. It 
should be noted however, that calpain knockout mice were described to 
exhibit increased platelet PTP1B levels as well as activity, which was 
associated with reduced thrombin-induced platelet aggregation, 
showing that PTP1B signaling is perhaps more complex [114]. While 
knock-out of calpain resulted in reduced in vivo thrombosis in mice, 
PTP1B knock-out mice showed similar occlusion times as wild type mice 
[114]. It should be noted however, that these were not conditional 
knock-out models. Interestingly, myeloid-specific knock-out of PTP1B 
from macrophages did reduce atherosclerosis in a mouse model [115]. 
Crosstalk between PTP1B and the serine/threonine phosphatase 
PP2A has also been shown. While PTP1B-mediated Src activation is 
required for αIIbβ3-mediated platelet adhesion, PP2A inhibits this pro-
cess, adding a layer of regulation and complexity [116]. Indeed, serine 
phosphatases may contribute to tyrosine phosphorylation patterns in 
platelets [117]. For instance, αIIbβ3-activated PP2A inhibits ERK 
signaling in response to ATP [118]. Thus, not all phosphatases are alike 
and it is their concerted actions that decide platelet fate. 
6.3. LMWPTP is activated upon collagen-induced signaling 
The presence of LMWPTP was first described in platelets by Mancini 
and colleagues as late as 2007 [119]. They showed that while this 
phosphatase is less abundant in platelets as compared to PTP1B, it is 
nevertheless functional in causing dephosphorylation of the FcγRII re-
ceptor ITAM motif, as well as LAT, causing inactivation of Syk and PLCγ 
and inhibition of platelet functions. Interestingly, despite the fact that 
Scr kinases have been shown to be an important target for LMWPTP in 
other cell types [119–121], Src phosphorylation in platelets in response 
thrombin, convulxin or FcγRIIA clustering did not appear to be affected 
by LMWPTP in the study of Mancini et al. [119]. On the other hand, 
another study showed that collagen induces LMWPTP, PTP1B and Src 
kinase activity, and that inhibition of this phosphatase activity is asso-
ciated with reduced Src activity and inhibition of platelet aggregation 
[22]. In addition, LAT is also a substrate for the kinases Syk and ZAP70, 
both of which are activated by LMWPTP [122,123]. Thus, the end result 
of LMWPTP activity in platelets may be activation rather than inacti-
vation of platelet signaling, depending on the platelet agonist. While 
LMWPTP may play an important role in platelet activation, the molec-
ular contribution of this phosphatase remains poorly understood. 
6.4. Other tyrosine phosphatases 
Very limited information is available concerning the other phos-
phatases expressed in platelets. PTEN (phosphatase and tensin homo-
logue deleted on chromosome 10) is a well-known tumor suppressor, 
which, when down-regulated or mutated, is correlated to cancer 
development and obesity. In platelets, a function for PTEN was 
described by Weng and colleagues (2010) [124] showing that platelets 
deficient for PTEN demonstrate increased collagen-induced aggregation 
and ATP secretion, as a result of enhanced activation of the PI3K-Akt 
pathway [123]. Thus, knockdown of PTEN reduced bleeding times in 
mice [124]. In contrast, knockdown of the protein tyrosine phosphatase 
PTPN7 (or hematopoietic protein tyrosine phosphatase (HePTP)), which 
acts as a negative modulator of ERK, regulating GPCR-signaling rather 
than GPVI signaling, only modestly affected bleeding times [125]. 
However, time to death in a pulmonary thromboembolism model was 
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enhanced upon PTPN7 knock-out in this study. ERK is also targeted by 
the Vaccinia H1-related (VHR) phosphatase, or dual-specificity phos-
phatase (DUSP) 3. In vivo knock down of DUSP3 in mice, as well as its 
chemical inhibition, causes a decrease of platelet aggregation efficiency, 
and reduces microvessel occlusion in thrombosis models [126]. Thus, 
conflicting results are seen upon knock-down of PTPN7 or DUSP3 
despite partial overlap in ERK modulation and in their signaling activity. 
6.5. Targeting the platelet-expressed phosphatases: perspective 
Investigation of the contribution of tyrosine phosphatases in platelets 
will likely emphasize their importance in diverse diseases, such car-
diovascular, cancer, metabolic diseases [127,128]. The next step may, 
therefore, be to focus on the development of better inhibitors of phos-
phatases. Unfortunately, the search for phosphatase inhibitors is limited 
by several factors, including lower selectivity and bioavailability [129]. 
Protein tyrosine phosphatases are characterized by a PTP motif: (V/H) 
CX5R, which is part of the phosphate-binding loop (P-loop) and makes it 
so complex to evaluate appropriate and selective inhibitors [130]. In 
addition, the presence of many holo-enzymes makes it difficult to pro-
duce selective (non-toxic) inhibitors for some (serine/threonine) kinases 
[131]. While many phosphatase inhibitors exist which are readily used 
in in vitro settings, many of these show poor selectivity, and none are 
used in the clinic thus far [132]. Nevertheless, with more and more 
evidence suggesting that phosphatases play a stronger role in platelet 
hyperactivity than previously anticipated, exploring this class of en-
zymes as druggable targets could present a step forward in the treatment 
of platelet-related diseases [133]. With this being widely recognized, 
efforts are now being made to develop novel discovery strategies to 
identify selective phosphatase inhibitors [132,134]. In addition, phase I 
trials with PP2A inhibitors for the use in cancer therapy have been 
completed, and show favorable toxicity profiles and efficacy. To what 
extent inhibition of phosphatases might modulate platelet responses in a 
clinical setting remains largely unexplored. Interestingly alternative 
opportunities to inhibit phosphatase function may exist. Some phos-
phatases, including SHP2 and LMWPTP are inactivated by oxidation by 
reactive oxygen species (ROS) production. For instance, collagen- 
induced ROS limits SHP2 activity, and treatment of platelets with the 
ROS scavenger Reversatrol prevents SHP2 activation, allows dephos-
phorylation of key signaling molecules such as Vav1, Btk and PLCγ, 
reduces aggregation [91,102], suggesting that ROS scavengers could 
play a role in the treatment of thrombovascular diseases. Recently, we 
demonstrated that targeting LMWPTP and PTP1B (using 3-bromopyru-
vate and CinnGEL, respectively) seems to disturb platelet function 
through Src inhibition. However, SHP1/2 inhibition (using NSC87887) 
did not affect platelet function (100 μM) [22]. Furthermore, our un-
published data also suggest that Trodusquemine (MSI-1436) and Clar-
amine (both PTP1B inhibitors), while modulating p38 and Src signaling, 
showed little effect on platelet aggregation. These data emphasize the 
need for better, more selective inhibitors, in order to exclude off target 
effects. 
7. Conclusions 
Platelets play an important role in many physiological processes, 
including hemostasis, wound healing and immunity. Impaired platelet 
function may contribute to several diseases, with over-activation of 
platelets having been related to, for instance, cardiovascular diseases 
and their complications. Thus, the elucidation of the molecular mech-
anism governing platelet functionality in health and disease may 
improve the treatment of such diseases. The role of phosphatases in 
these processes is slowly gaining attention, but their roles are as complex 
as the multitude of signaling events regulating platelet functions 
themselves. Both positive and negative modulatory roles for these en-
zymes have been described, and it is clear that selectivity towards ag-
onists exists for these proteins in platelets. However, differences in 
agonists used, read-outs for platelet reactivity and methods of studying 
phosphatase activity and their downstream targets hamper interpreta-
tion of the limited experimental evidence. Thus the role of phosphatases 
in platelet biology warrants further investigation. A better understand-
ing of these phosphatases, the way they themselves are regulated and 
the pathways they modulate, may contribute to the discovery of new 
potential pharmacological targets. 
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[138] Z. Simon, A. Kiss, F. Erdödi, H. Setiadi, I. Beke Debreceni, B. Nagy Jr., 
J. Kappelmayer, Protein phosphatase inhibitor calyculin-a modulates activation 
markers in TRAP-stimulated human platelets, Platelets. 21 (7) (2010) 555–562, 
https://doi.org/10.3109/09537104.2010.499156. 
[139] R. Polanowska-Grabowska, C.G. Simon Jr., R. Falchetto, J. Shabanowitz, D. 
F. Hunt, A.R. Gear, Platelet adhesion to collagen under flow causes dissociation of 
a phosphoprotein complex of heat-shock proteins and protein phosphatase 1, 
Blood. 90 (4) (1997) 1516–1526. 
[140] Y. Wang, E. Vachon, J. Zhang, V. Cherepanov, J. Kruger, J. Li, K. Saito, 
P. Shannon, N. Bottini, H. Huynh, H. Ni, H. Yang, C. McKerlie, S. Quaggin, Z. 
J. Zhao, P.A. Marsden, T. Mustelin, K.A. Siminovitch, G.P. Downey, Tyrosine 
phosphatase MEG2 modulates murine development and platelet and lymphocyte 
activation through secretory vesicle function, J. Exp. Med. 202 (11) (2005) 
1587–1597, https://doi.org/10.1084/jem.20051108. 
[141] R. Craig, J.P. Cortens, R.C. Beavis, Open source system for analyzing, validating, 
and storing protein identification data, J. Proteome Res. 3 (6) (2004) 1234–1242, 
https://doi.org/10.1021/pr049882h. 
A.V.S. Faria et al.                                                                                                                                                                                                                              
BBA - Molecular Cell Research 1868 (2021) 118927
11
[142] M. Dittrich, I. Birschmann, J. Pfrang, S. Herterich, A. Smolenski, U. Walter, 
T. Dandekar, Analysis of SAGE data in human platelets: features of the 
transcriptome in an anucleate cell, Thromb. Haemost. 95 (4) (2006) 643–651. 
[143] U. Lewandrowski, S. Wortelkamp, K. Lohrig, R.P. Zahedi, D.A. Wolters, U. Walter, 
A. Sickmann, Platelet membrane proteomics: a novel repository for functional 
research, Blood. 114 (1) (2009) e10–e19, https://doi.org/10.1182/blood-2009- 
02-203828. 
[144] J. Moebius, R.P. Zahedi, U. Lewandrowski, C. Berger, U. Walter, A. Sickmann, The 
human platelet membrane proteome reveals several new potential membrane 
proteins, Mol. Cell. Proteomics 4 (11) (2005) 1754–1761, https://doi.org/ 
10.1074/mcp.M500209-MCP200. 
A.V.S. Faria et al.                                                                                                                                                                                                                              
